Suppr
超能文献

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.

作者信息

Wenzel Joerg, van Holt Nadine, Maier Judith, Vonnahme Maria, Bieber Thomas, Wolf Dominik

机构信息

Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany.

出版信息

J Invest Dermatol. 2016 Jun;136(6):1281-1283. doi: 10.1016/j.jid.2016.02.015. Epub 2016 Feb 23.

DOI:10.1016/j.jid.2016.02.015

PMID:26916391

Abstract

摘要

相似文献

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.

J Invest Dermatol. 2016 Jun;136(6):1281-1283. doi: 10.1016/j.jid.2016.02.015. Epub 2016 Feb 23.

Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.

Ann Rheum Dis. 2019 Mar;78(3):431-433. doi: 10.1136/annrheumdis-2018-214037. Epub 2018 Oct 3.

JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.

Exp Dermatol. 2017 Aug;26(8):728-730. doi: 10.1111/exd.13253. Epub 2017 May 3.

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.

Cytokine Growth Factor Rev. 2020 Aug;54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20.

Ruxolitinib.

Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16.

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.

Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10.

Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.

Front Immunol. 2020 Mar 3;11:344. doi: 10.3389/fimmu.2020.00344. eCollection 2020.

Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.

Blood. 2024 Jul 11;144(2):238. doi: 10.1182/blood.2024024626.

Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.

Future Oncol. 2011 Sep;7(9):1035-43. doi: 10.2217/fon.11.81.

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.

J Allergy Clin Immunol. 2016 Dec;138(6):1752-1755. doi: 10.1016/j.jaci.2016.07.015. Epub 2016 Aug 20.

引用本文的文献

Mechanism and target treatment of primary immunodeficiency diseases with systemic lupus erythematosus-like phenotype.

Pediatr Discov. 2024 May 27;2(3):e67. doi: 10.1002/pdi3.67. eCollection 2024 Sep.

Recent Advances of Type I Interferon on the Regulation of Immune Cells and the Treatment of Systemic Lupus Erythematosus.

J Inflamm Res. 2025 Mar 30;18:4533-4549. doi: 10.2147/JIR.S516195. eCollection 2025.

Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.

Front Immunol. 2025 Feb 5;16:1449693. doi: 10.3389/fimmu.2025.1449693. eCollection 2025.

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report.

Clin Cosmet Investig Dermatol. 2023 Oct 9;16:2793-2800. doi: 10.2147/CCID.S419344. eCollection 2023.

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition.

Front Med (Lausanne). 2023 Jun 29;10:1217147. doi: 10.3389/fmed.2023.1217147. eCollection 2023.

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus.

J Inflamm Res. 2023 Apr 6;16:1471-1478. doi: 10.2147/JIR.S397639. eCollection 2023.

Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?

Int J Mol Sci. 2022 Oct 4;23(19):11788. doi: 10.3390/ijms231911788.

An update on the management of refractory cutaneous lupus erythematosus.

Front Med (Lausanne). 2022 Sep 23;9:941003. doi: 10.3389/fmed.2022.941003. eCollection 2022.

Treatment of cutaneous lupus with topical ruxolitinib cream.

JAAD Case Rep. 2022 Aug 28;28:133-135. doi: 10.1016/j.jdcr.2022.08.038. eCollection 2022 Oct.

Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

Clin Cosmet Investig Dermatol. 2022 Sep 8;15:1815-1831. doi: 10.2147/CCID.S382628. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.

J Invest Dermatol. 2016 Jun;136(6):1281-1283. doi: 10.1016/j.jid.2016.02.015. Epub 2016 Feb 23.

Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.

Ann Rheum Dis. 2019 Mar;78(3):431-433. doi: 10.1136/annrheumdis-2018-214037. Epub 2018 Oct 3.

JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.

Exp Dermatol. 2017 Aug;26(8):728-730. doi: 10.1111/exd.13253. Epub 2017 May 3.

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.

Cytokine Growth Factor Rev. 2020 Aug;54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20.

Ruxolitinib.

Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16.

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.

Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10.

Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.

Front Immunol. 2020 Mar 3;11:344. doi: 10.3389/fimmu.2020.00344. eCollection 2020.

Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.

Blood. 2024 Jul 11;144(2):238. doi: 10.1182/blood.2024024626.

Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.

Future Oncol. 2011 Sep;7(9):1035-43. doi: 10.2217/fon.11.81.

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.

J Allergy Clin Immunol. 2016 Dec;138(6):1752-1755. doi: 10.1016/j.jaci.2016.07.015. Epub 2016 Aug 20.

引用本文的文献

Mechanism and target treatment of primary immunodeficiency diseases with systemic lupus erythematosus-like phenotype.

Pediatr Discov. 2024 May 27;2(3):e67. doi: 10.1002/pdi3.67. eCollection 2024 Sep.

Recent Advances of Type I Interferon on the Regulation of Immune Cells and the Treatment of Systemic Lupus Erythematosus.

J Inflamm Res. 2025 Mar 30;18:4533-4549. doi: 10.2147/JIR.S516195. eCollection 2025.

Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.

Front Immunol. 2025 Feb 5;16:1449693. doi: 10.3389/fimmu.2025.1449693. eCollection 2025.

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report.

Clin Cosmet Investig Dermatol. 2023 Oct 9;16:2793-2800. doi: 10.2147/CCID.S419344. eCollection 2023.

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition.

Front Med (Lausanne). 2023 Jun 29;10:1217147. doi: 10.3389/fmed.2023.1217147. eCollection 2023.

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus.

J Inflamm Res. 2023 Apr 6;16:1471-1478. doi: 10.2147/JIR.S397639. eCollection 2023.

Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?

Int J Mol Sci. 2022 Oct 4;23(19):11788. doi: 10.3390/ijms231911788.

An update on the management of refractory cutaneous lupus erythematosus.

Front Med (Lausanne). 2022 Sep 23;9:941003. doi: 10.3389/fmed.2022.941003. eCollection 2022.

Treatment of cutaneous lupus with topical ruxolitinib cream.

JAAD Case Rep. 2022 Aug 28;28:133-135. doi: 10.1016/j.jdcr.2022.08.038. eCollection 2022 Oct.

Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

Clin Cosmet Investig Dermatol. 2022 Sep 8;15:1815-1831. doi: 10.2147/CCID.S382628. eCollection 2022.

Suppr超能文献

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译